UK approves Pfizer-BioNTech's COVID booster targeting Omicron BA.4/5
- Wall St rallies as Fed's Powell nods to easing inflation after rate hike
- Meta Platforms shares surge 17% on Q4 revenue beat while profits fall 55%
- Fed's Powell says could raise rates beyond December, gives nod to disinflation
- Fed hikes by 0.25% in further downshift on tightening, but sees more hikes ahead
- AMD shares rise after Q4 report that beat expectations for revenue, EPS
FILE PHOTO: Test tubes are seen in front of displayed Pfizer and Biontech logos in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration/File Photo
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
By Pushkala Aripaka
(Reuters) -Britain's health regulator on Wednesday approved the country's first two-pronged COVID-19 booster targeting the Omicron BA.4 and BA.5 sub-variants and the original coronavirus strain.
The Medicines and Healthcare products Regulatory Agency (MHRA) said the vaccine from Pfizer and partner BioNTech was approved for use as a booster in people 12 years and older after it was found to meet safety, quality and effectiveness standards.
Britain had already approved so-called bivalent vaccines targeting the Omicron BA.1 sub-variant from Pfizer-BioNTech and rival Moderna, but now has added a first against BA.4/5 in its arsenal with the latest authorisation.
The regulator on Wednesday also approved Novavax's COVID-19 shot as a booster for adults.
"All approved COVID booster vaccines help to improve the protection obtained from earlier doses of the vaccine and help give longer-term protection against getting seriously ill from COVID-19," the MHRA said.
The UK has recorded more than 23 million COVID-19 infections and over 190,000 deaths, the seventh-highest globally, according to the World Health Organization (WHO), with about 150 million vaccine doses having been given by early September for a population of around 67 million.
Omicron sub-variants BA.4/5 dominated the summer and are still behind the majority of infections globally, but newer Omicron sub-variants are gaining ground, with hundreds of them being tracked by scientists, WHO officials said last month.
While existing COVID-19 vaccines continue to provide good protection against hospitalisation and death, vaccine effectiveness has taken a hit as the coronavirus, which originally emerged in China in December 2019, has evolved.
Warnings over a possible "twindemic" of COVID-19 and flu have also been issued by UK officials after the end of restrictions meant increased social contact.
Pfizer and BioNTech last week said their shot tailored to BA.4/5 produced a strong antibody response in older adults than the original shot after one month, and in October said it generated a strong immune response.
Healthcare regulators for the European Union, the United States and Canada had already approved the retooled Pfizer-BioNTech shot last month.
(Reporting by Pushkala Aripaka in Bengaluru; Editing by Shounak Dasgupta and Mark Potter)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pfizer (PFE) PT Lowered to $45 at UBS
- Celularity (CELU) Receives Preliminary Assessment of Product Classification and Jurisdiction for CTW to be Regulated as a Device
- Peru's Congress rejects proposal for 2023 elections, debate continues
Create E-mail Alert Related CategoriesFDA, Reuters
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!